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records of pharmacists at six Scottish cancer treatment centres
and units was undertaken where a standardised care plan (Mac-
intyre et al. Development of a system for reporting pharmaceu-
tical care issues in cancer patients receiving chemotherapy.
Pharm J 2003;271:266–7) was utilised. Records were entered
into an electronic version of the care plan and activities were
recorded according to deﬁnitions by McAnaw (McAnaw JJ.
Development of novel approaches to demonstrate the quality of
drug therapy use. PhD thesis. Glasgow: University of Strathclyde.
2003). Categorisation system for pharmaceutical care issues was
utilised and its reliability was assessed with Cohen’s Kappa.
RESULTS: A total of 2737 pharmaceutical care issues were
recorded from 729 patients receiving 3376 cycles of chemother-
apy (0.8 care issues per cycle), 2711 care issues were categorised
into Drug Therapy Problems (DTP’s) as deﬁned by Cipolle et al.
(Cipolle RJ et al. Identifying, resolving, and preventing drug
therapy problems: the pharmacist’s responsibility. In: Pharma-
ceutical Care Practice. New York: McGraw-Hill. 1998). Relia-
bility of the categorisation assessed with Cohen’s Kappa was
found to be at least “good” (Kappa between 0.60 and 0.75) in
all but one categories tested. The most common DTP addressed
was “adverse drug reaction” (77%). Others included “dose too
high/dose too low” (9%) and “additional medication needs”
(8%). Care issues were also categorised as “checks” (67%) or
“changes” (33%). Checks were mainly “veriﬁcations” prior to
administration (75%) rather than ongoing “monitoring” (25%).
Changes were “modiﬁcations” (49%), individualised “adjust-
ments” (38%) or “prompted revisions” of the treatment (13%).
CONCLUSIONS: Results show the system’s potential to
promote standardised documentation of pharmaceutical care
delivered to patients undergoing cancer chemotherapy as an
important contribution to quality assurance in cancer
chemotherapy.
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OBJECTIVES: Cancer is the second leading cause of death in the
United States and a major contributor to health care expendi-
tures. Our objective was to investigate whether disparities in 
outpatient treatment costs exist among an economically homoge-
nous group—those on Medicaid. METHODS: Utilizing Mary-
land Medicaid administrative claims data, a retrospective cohort
design was employed to examine disparities in ambulatory treat-
ment costs of breast, colorectal and prostate cancer treatments
by region, race and gender. We report mean and median results
by each demographic category and test for the statistical signif-
icance of each. Lorenz curves are plotted and Gini coefﬁcients
calculated for each type of cancer. RESULTS: We do not ﬁnd a
consistent trend in ambulatory costs across the 3 cancers by tra-
ditional demographic variables. Lorenz curves indicate highly
unequal distributions of costs. Gini coefﬁcients are 0.687 for
breast cancer, 0.757 for colorectal cancer, and 0.774 for prostate
cancer. CONCLUSIONS: Signiﬁcant variation in non-hospital
based expenditures exists for breast, colorectal and prostate
cancers in a population of homogeneous socio-economic status
and uniform insurance entitlement. Observed individual level
disparities are not consistent across cancers by region, race or
gender, but the majority of this low income population receives
very little ambulatory care.
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OBJECTIVES: To assess patient outcomes of various strategies
for determining diagnosis and resectability in patients with sus-
pected pancreatic cancer (PC). METHODS: We used data from
a prospective study of 193 patients with suspected PC performed
at the Charité University Hospital from August, 1999–Novem-
ber, 2000. These patients underwent each of the following six
different diagnostic procedures: ultrasound (US), magnetic reso-
nance imaging (MR), computed tomography (CT), endoscopic
ultrasound (EUS), ﬂuorodeoxyglucose positron emissiontomog-
raphy (PET), and endoscopic retrograde cholangiopancreaticog-
raphy (ERCP). We developed a decision tree to predict diagnostic
accuracy and resectability using the conditional probabilities
derived from our study. In the ﬁrst step, we sought to maximize
the number of patients having both diagnostic and resectability
state correctly classiﬁed. As the varying types of incorrect assess-
ments lead to different clinical consequences, we determined a
clinical consequence score to assess the impact of these conse-
quences on mortality and quality of life (e.g. inadequate treat-
ment following an imperfect classiﬁcation). This score ranged
from 100 (best scenario, benign diagnosed as benign) to 0 (worst
scenario, benign and unresectable classiﬁed as resectable). Each
possible scenario’s score was estimated by a clinical panel of
experts. In the second step, these score values were incorporated
into the decision tree as patient outcome weights. RESULTS:
Regarding correct classiﬁcation, best test performance was
achieved with MR alone, correctly classifying 79% of patients
as benign, malignant/resectable, or malignant/unresectable. The
combination of PET and EUS had the worst performance with
only 61% of patients correctly classiﬁed. The incorporation of
the clinical consequence score lead only to minor differences
between the strategies. Probabilistic sensitivity analysis showed
robust results in both portions of the study. CONCLUSIONS:
The incorporation of the clinical consequence score failed to
determine a superior strategy. Once quality-adjusted life years
and costs are estimated, we will perform a cost-effectiveness
analysis.
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OBJECTIVE: To use meta-analysis techniques to pool both clin-
ical effect and cost data to provide an absolute estimate of 
the likely survival and cost of BSC in advanced NSCLC.
METHODS: A systematic review of published clinical and eco-
nomic literature identiﬁed patient cohorts with stage IIIb and IV
NSCLC receiving BSC at any stage of treatment. Data on 12
month, 24 month and median survival, as well as cost of BSC,
were extracted from the original publications. With appropriate
ﬁxed and random effect meta-analysis techniques, data of com-
